日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis

硼-截短侧耳素作为抗沃尔巴克氏体剂具有治疗盘尾丝虫病和淋巴丝虫病的潜力

Robert T Jacobs, Christopher S Lunde, Yvonne R Freund, Vincent Hernandez, Xianfeng Li, Yi Xia, David S Carter, Pamela W Berry, Jason Halladay, Fernando Rock, Rianna Stefanakis, Eric Easom, Jacob J Plattner, Louise Ford, Kelly L Johnston, Darren A N Cook, Rachel Clare, Andrew Cassidy, Laura Myhill, H

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors

4-氨基吡啶苯甲酰胺支架的先导优化,以鉴定有效、选择性且可口服生物利用的 TYK2 抑制剂

Jun Liang, Anne van Abbema, Mercedesz Balazs, Kathy Barrett, Leo Berezhkovsky, Wade Blair, Christine Chang, Donnie Delarosa, Jason DeVoss, Jim Driscoll, Charles Eigenbrot, Nico Ghilardi, Paul Gibbons, Jason Halladay, Adam Johnson, Pawan Bir Kohli, Yingjie Lai, Yanzhou Liu, Joseph Lyssikatos, Priscil

Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900

联合用药方案为口服生物可利用的选择性 ChK1 抑制剂 GNE-900 对吉西他滨的化学增强作用定义了一个“机会窗口”

Elizabeth Blackwood, Jennifer Epler, Ivana Yen, Michael Flagella, Tom O'Brien, Marie Evangelista, Stephen Schmidt, Yang Xiao, Jonathan Choi, Kaska Kowanetz, Judi Ramiscal, Kenton Wong, Diana Jakubiak, Sharon Yee, Gary Cain, Lewis Gazzard, Karen Williams, Jason Halladay, Peter K Jackson, Shiva Malek

GDC-0449-a potent inhibitor of the hedgehog pathway

GDC-0449-一种强效的 Hedgehog 通路抑制剂

Kirk D Robarge, Shirley A Brunton, Georgette M Castanedo, Yong Cui, Michael S Dina, Richard Goldsmith, Stephen E Gould, Oivin Guichert, Janet L Gunzner, Jason Halladay, Wei Jia, Cyrus Khojasteh, Michael F T Koehler, Karen Kotkow, Hank La, Rebecca L Lalonde, Kevin Lau, Leslie Lee, Derek Marshall, Jam